Posted by Michael Wonder on 02 Apr 2025
Sydnexis announces positive CHMP opinion in Europe for SYD-101 for slowing the progression of paediatric myopia
1 April 2025 - Santen is Sydnexis’ licensing partner to commercialise SYD-101 within the EMEA region upon issuance of a marketing authorisation by the European Commission
Sydnexis today announced that the EMA's CHMP has granted a positive opinion for its proprietary low dose atropine formulation, SYD-101, for slowing the progression of paediatric myopia.
